Canada Infectious Disease Therapeutics Market Report 2022 to 2030

Canada Infectious Disease Therapeutics Market Analysis

$ 3999

Canada's infectious disease therapeutics market is likely to grow at a CAGR of 4.35% from a market size of $9.59 Bn in 2022 to $13.48 Bn in 2030. The increase in the prevalence of infectious diseases in Canada and the increasing government initiatives to provide facilities to patients have acted as a market growth driver. This report is segmented by mode of treatment, applications, disease type, target organisms, and end user. Some key players in this market include Novartis, Roche, Janssen Pharmaceutical, Merck, BI, and others.

ID: IN10CAPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Dhruv Joshi

Buy Now

Canada Infectious Disease Therapeutics Market Executive Summary

Canada's infectious disease therapeutics market size is at around $9.59 Bn in 2022 and is projected to reach $13.48 Bn in 2030, exhibiting a CAGR of 4.35% during the forecast period 2022-2030. Canada is the western hemisphere's largest country and one of the world's largest. It has a vibrant free-market economy, with businesses ranging from small owner-managed enterprises to multinational companies. Historically, Canada's economy was built on the export of agricultural staples, particularly grain, as well as the manufacture and sale of natural resource exports including minerals, oil and gas, and forest products.

The total number of medicine purchases in Canada is anticipated to increase. The outpatient sector is predicted to continue seeing moderate levels of growth in drug spending (3% to 4%), whereas hospital settings are predicted to see higher rates of growth (7% to 8%). Around 307,205 deaths have been occurred in 2020 due to infectious diseases in Canada. Out of all these deaths, 96 deaths were due to Tuberculosis, 135 were due to HIV, and 94 deaths were due to viral infections of the central nervous system. Emerging infectious diseases (EIDs), including West Nile virus, severe acute respiratory syndrome (SARS), and Lyme disease, have had a direct effect within Canada, while many more EIDs such as Zika, chikungunya, and Ebola are a threat to Canadians while traveling.

canada infectious disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

A significant possibility for the market's expansion is the enormous population of individuals who fall under the genetic category. The increase in the average person's discretionary income has also become a significant potential. Those with high disposable incomes can choose to receive cutting-edge medical care, which supports the market's expansion. The rising incidence of infectious diseases in society has been identified as a key driver of the therapeutic system's expansion. To increase earnings, major market companies have introduced cutting-edge drugs to treat infectious diseases. The government has taken steps to provide citizens with cutting-edge facilities for the treatment of infectious diseases. The development of new drugs for the treatment of infectious diseases also acts as a growth driver for the Canada infectious disease therapeutics market.

Market Restraints

The lack of skilled professionals treating infectious disease patients hampers the market growth. There is a high cost of treatment of infectious diseases which also acts as a burden to the patients hence affecting the market growth. The lack of trained workers in the industry, which significantly restrains the market's growth, is a major problem for the infectious disease therapeutics market. The market's rising demand for generic medications has put pressure on the growth of branded medications for infectious disorders.

Competitive Landscape

Key Players

Novartis
Roche
Janssen Pharmaceutlcal
Merck
Boehringer Ingelheim
Sanofi
AstraZeneca
GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

The federal health portfolio includes the Public Health Agency of Canada. Its efforts are centered on preventing illness and injury, addressing threats to public health, promoting excellent physical and mental health, and disseminating knowledge to assist in making informed decisions. Access to safe and effective medicines and healthcare items is actively protected by Health Canada. The Department makes an effort to balance the risks and benefits to health that each medicine and medical product may have. Public safety is given top importance when deciding how to strike a balance. The department strives to reduce the health risks to you and increase the safety offered by the regulatory system for these items by collaborating with other levels of government, healthcare professionals, patient and consumer interest groups, research communities, and manufacturers.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.